Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMIESYM)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Desmethylclomipramine; Norclomipramine; UNII-01DN47PPQG; 01DN47PPQG; N-Demethylclomipramine; Demethylchlorimipramine; Desmethylchlorimipramine; AC1LDNXR; SCHEMBL11384662; VPIXQGUBUKFLRF-UHFFFAOYSA-N; CHEBI:124969; ZINC2570877; API0007900; BRD-K52696183-003-01-0; 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N-methyl-; 3-Chloro-10,11-dihydro-N-methyl-5H-dibenz(b,f)azepine-5-propanamine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Fibroblast
Nasopharyngeal carcinoma
|
||||||||||||||||||||||||
